PUBLISHER: 360iResearch | PRODUCT CODE: 1608967
PUBLISHER: 360iResearch | PRODUCT CODE: 1608967
Malabsorption Syndrome Market by Treatment (Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents), Disease Type (Cystic Fibrosis, Lactose Intolerance, Sprue), End-user - Global Forecast 2025-2030
The Malabsorption Syndrome Market was valued at USD 2.34 billion in 2023, expected to reach USD 2.49 billion in 2024, and is projected to grow at a CAGR of 5.66%, to USD 3.45 billion by 2030.
Malabsorption Syndrome encompasses a range of disorders characterized by the intestine's inability to adequately absorb nutrients, vitamins, and minerals from food. The necessity of addressing this syndrome is underscored by its potential to cause severe nutritional deficiencies, leading to an increased demand for diagnostics and treatment options. Its applications span the healthcare sector, particularly focusing on gastrointestinal health products, dietary supplements, and medical diagnostics. Key end-users include hospitals, clinics, and specialized medical centers that diagnose, treat, and manage malabsorption-related conditions. The market for Malabsorption Syndrome management is primarily driven by the rising prevalence of gastrointestinal disorders, aging populations more prone to nutrient deficiencies, and increasing awareness regarding digestive health. Technological advancements in diagnostic tools and treatment options present lucrative opportunities for market growth. For instance, the development of advanced imaging techniques and non-invasive testing methods for early diagnosis is critical. Growth is also supported by a surge in demand for nutritional supplements designed to counter specific deficiencies. However, market expansion faces significant challenges, such as high treatment costs, lack of awareness in developing regions, and inadequate healthcare infrastructure. Furthermore, the complexity of accurately diagnosing the syndrome can impede timely treatment, hindering market momentum. Innovation and research opportunities abound within this market, especially in formulating comprehensive treatment regimens that integrate dietary management with pharmacotherapy. Companies can also benefit from investing in more accessible and cost-effective diagnostic solutions. With the market's evolving nature, a multidisciplinary approach encompassing cutting-edge research, product development, and patient education initiatives could prove highly advantageous. Strengthening collaborations with healthcare providers to enhance diagnosis and treatment accessibility is recommended as a strategic move to tap into potential market segments and foster growth.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 2.34 billion |
| Estimated Year [2024] | USD 2.49 billion |
| Forecast Year [2030] | USD 3.45 billion |
| CAGR (%) | 5.66% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malabsorption Syndrome Market
The Malabsorption Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rising number of lactose intolerance consumers
- Favorable government initiatives and awareness campaigns for malabsorption syndrome
- Growing incidences of cause disorders such as celiac disease and other digestive diseases
- Market Restraints
- Lack of proper healthcare infrastructure
- Market Opportunities
- Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
- Investments and development of novel medicines
- Market Challenges
- Stringent safety rules and product recalls
Porter's Five Forces: A Strategic Tool for Navigating the Malabsorption Syndrome Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malabsorption Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Malabsorption Syndrome Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malabsorption Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Malabsorption Syndrome Market
A detailed market share analysis in the Malabsorption Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malabsorption Syndrome Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malabsorption Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Malabsorption Syndrome Market
A strategic analysis of the Malabsorption Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Malabsorption Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Ache Laboratorios Farmaceuticos S.A., AstraZeneca PLC, Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Koninklijke Philips N.V., Merck & Co., Inc., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., and Tillotts Pharma AG.
Market Segmentation & Coverage
This research report categorizes the Malabsorption Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Treatment, market is studied across Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents, Gluten-Free Diet, Nutritional Supplements, and Protease & Lipase Supplements.
- Based on Disease Type, market is studied across Cystic Fibrosis, Lactose Intolerance, and Sprue.
- Based on End-user, market is studied across Academic & Research Institutes, Hospitals, Nutrition Clinics, and Pharmaceutical Companies.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising number of lactose intolerance consumers
- 5.1.1.2. Favorable government initiatives and awareness campaigns for malabsorption syndrome
- 5.1.1.3. Growing incidences of cause disorders such as celiac disease and other digestive diseases
- 5.1.2. Restraints
- 5.1.2.1. Lack of proper healthcare infrastructure
- 5.1.3. Opportunities
- 5.1.3.1. Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
- 5.1.3.2. Investments and development of novel medicines
- 5.1.4. Challenges
- 5.1.4.1. Stringent safety rules and product recalls
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Malabsorption Syndrome Market, by Treatment
- 6.1. Introduction
- 6.2. Anti-Inflammatory Drugs
- 6.3. Antibiotics
- 6.4. Antidiarrheal Agents
- 6.5. Gluten-Free Diet
- 6.6. Nutritional Supplements
- 6.7. Protease & Lipase Supplements
7. Malabsorption Syndrome Market, by Disease Type
- 7.1. Introduction
- 7.2. Cystic Fibrosis
- 7.3. Lactose Intolerance
- 7.4. Sprue
8. Malabsorption Syndrome Market, by End-user
- 8.1. Introduction
- 8.2. Academic & Research Institutes
- 8.3. Hospitals
- 8.4. Nutrition Clinics
- 8.5. Pharmaceutical Companies
9. Americas Malabsorption Syndrome Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Malabsorption Syndrome Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Malabsorption Syndrome Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Abbvie Inc.
- 2. Ache Laboratorios Farmaceuticos S.A.
- 3. AstraZeneca PLC
- 4. Bausch Health Companies Inc.
- 5. Baxter International Inc.
- 6. Bayer AG
- 7. Gilead Sciences, Inc.
- 8. GlaxoSmithKline PLC
- 9. Koninklijke Philips N.V.
- 10. Merck & Co., Inc.
- 11. Novartis AG
- 12. Perrigo Company PLC
- 13. Pfizer Inc.
- 14. Sanofi S.A.
- 15. Tillotts Pharma AG
LIST OF FIGURES
- FIGURE 1. MALABSORPTION SYNDROME MARKET RESEARCH PROCESS
- FIGURE 2. MALABSORPTION SYNDROME MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 13. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 15. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 21. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. MALABSORPTION SYNDROME MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. MALABSORPTION SYNDROME MARKET DYNAMICS
- TABLE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIDIARRHEAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY GLUTEN-FREE DIET, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PROTEASE & LIPASE SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY LACTOSE INTOLERANCE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY SPRUE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITION CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 22. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 23. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 24. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 25. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 26. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 27. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 28. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 29. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 30. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 31. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 32. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 33. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 34. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 35. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 36. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 37. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 38. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 39. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 40. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 41. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 42. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 43. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 44. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 45. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 46. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 47. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 48. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 49. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 50. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 51. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 52. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 53. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 54. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 55. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 56. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 57. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 58. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 59. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 60. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 61. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 62. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 63. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 64. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 66. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 67. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 68. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 69. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 70. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 71. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 72. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 73. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 74. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 75. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 76. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 77. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 78. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 79. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 80. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 81. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 82. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 85. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 86. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 87. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 88. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 89. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 90. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 91. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 92. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 94. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 95. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 96. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 97. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 98. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 99. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 100. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 101. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 102. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 103. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 104. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 105. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 106. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 107. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 108. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 109. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 110. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 111. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 112. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 113. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 114. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 115. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 116. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 117. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 118. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 119. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 120. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 121. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 122. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 123. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 124. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 125. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 126. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 127. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 128. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 129. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 130. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 131. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 132. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 133. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 134. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 135. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 136. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 137. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 138. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 139. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 140. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 141. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 142. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 143. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 144. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 145. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 146. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 147. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 148. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
- TABLE 149. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 150. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 151. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
